Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artivion, Inc. stock logo
AORT
Artivion
$28.21
-1.8%
$26.46
$21.97
$32.33
$1.20B1.62334,100 shs241,639 shs
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$34.46
-4.7%
$32.37
$27.07
$40.28
$1.40B1.36255,904 shs569,607 shs
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$11.54
-4.5%
$12.79
$5.11
$19.22
$322.99M0.93243,862 shs299,175 shs
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$20.76
-0.8%
$19.85
$15.75
$48.24
$1.38B1.521.50 million shs1.10 million shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artivion, Inc. stock logo
AORT
Artivion
-0.92%-1.32%-0.62%+19.03%+21.88%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
+0.11%+6.46%-0.06%+7.27%+6.19%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-5.99%-5.85%-14.93%-5.63%+113.43%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-2.92%+1.26%-9.55%+9.13%-55.82%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artivion, Inc. stock logo
AORT
Artivion
2.471 of 5 stars
1.65.00.00.02.22.51.9
Cadre Holdings, Inc. stock logo
CDRE
Cadre
3.0126 of 5 stars
1.53.02.50.03.03.31.9
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
2.8295 of 5 stars
3.54.00.00.02.90.80.6
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
4.1432 of 5 stars
4.21.00.04.92.80.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artivion, Inc. stock logo
AORT
Artivion
3.17
Buy$31.4011.31% Upside
Cadre Holdings, Inc. stock logo
CDRE
Cadre
2.50
Moderate Buy$37.508.82% Upside
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
3.00
Buy$25.00116.64% Upside
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2.43
Hold$34.1564.52% Upside

Current Analyst Ratings Breakdown

Latest CLPT, CDRE, TNDM, and AORT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$45.00 ➝ $38.00
5/22/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.00
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
Citizens Jmp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$33.00 ➝ $33.00
5/6/2025
Artivion, Inc. stock logo
AORT
Artivion
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$58.00 ➝ $59.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$60.00 ➝ $31.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$36.00 ➝ $30.00
5/1/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$33.00 ➝ $24.00
4/10/2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$20.00
(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artivion, Inc. stock logo
AORT
Artivion
$390.08M3.09$0.77 per share36.78$6.87 per share4.11
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$559.81M2.50$1.51 per share22.89$5.25 per share6.56
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
$32.24M10.02N/AN/A$0.86 per share13.42
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
$982.95M1.41N/AN/A$4.81 per share4.32
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artivion, Inc. stock logo
AORT
Artivion
-$30.69M-$0.50N/A56.42N/A-0.22%5.15%1.91%8/6/2025 (Estimated)
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$38.64M$0.9541.5225.341.586.34%12.88%6.06%8/8/2025 (Estimated)
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$22.09M-$0.76N/AN/AN/A-59.64%-62.10%-38.39%8/6/2025 (Estimated)
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$222.61M-$2.78N/AN/AN/A-14.84%-44.19%-11.99%7/30/2025 (Estimated)

Latest CLPT, CDRE, TNDM, and AORT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
-$0.15-$0.22-$0.07-$0.22$8.21 million$8.49 million
5/6/2025Q1 2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$0.13$0.23+$0.10$0.23$121.53 million$130.11 million
5/5/2025Q1 2025
Artivion, Inc. stock logo
AORT
Artivion
$0.12$0.06-$0.06-$0.01$94.81 million$98.98 million
4/30/2025Q1 2025
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artivion, Inc. stock logo
AORT
Artivion
N/AN/AN/AN/AN/A
Cadre Holdings, Inc. stock logo
CDRE
Cadre
$0.381.10%N/A40.00%2 Years
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/AN/AN/AN/AN/A
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/AN/AN/AN/AN/A

Latest CLPT, CDRE, TNDM, and AORT Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/22/2025
Cadre Holdings, Inc. stock logo
CDRE
Cadre
quarterly$0.09501.29%5/2/20255/2/20255/16/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artivion, Inc. stock logo
AORT
Artivion
0.71
1.88
1.33
Cadre Holdings, Inc. stock logo
CDRE
Cadre
0.65
3.01
1.96
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
N/A
4.54
3.61
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.29
2.90
2.32

Institutional Ownership

CompanyInstitutional Ownership
Artivion, Inc. stock logo
AORT
Artivion
86.37%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
43.95%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
30.08%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
N/A

Insider Ownership

CompanyInsider Ownership
Artivion, Inc. stock logo
AORT
Artivion
7.60%
Cadre Holdings, Inc. stock logo
CDRE
Cadre
37.00%
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
6.97%
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
1.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artivion, Inc. stock logo
AORT
Artivion
1,30042.70 million38.52 millionOptionable
Cadre Holdings, Inc. stock logo
CDRE
Cadre
2,24040.66 million25.58 millionOptionable
ClearPoint Neuro, Inc. stock logo
CLPT
ClearPoint Neuro
11027.99 million25.90 millionOptionable
Tandem Diabetes Care, Inc. stock logo
TNDM
Tandem Diabetes Care
2,60066.61 million64.23 millionOptionable

Recent News About These Companies

Abbott to pair glucose-ketone sensor with Tandem's insulin pumps
Tandem agrees to pay $36M to settle Roche patent litigation

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artivion stock logo

Artivion NYSE:AORT

$28.21 -0.53 (-1.84%)
Closing price 03:59 PM Eastern
Extended Trading
$28.24 +0.03 (+0.11%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Cadre stock logo

Cadre NYSE:CDRE

$34.46 -1.69 (-4.67%)
Closing price 03:59 PM Eastern
Extended Trading
$34.42 -0.05 (-0.13%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cadre Holdings, Inc. manufactures and distributes safety that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It offers body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brand names; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, the Department of Energy, Los Alamos National Laboratories, Waste Isolation Plant, and various foreign government agencies. Cadre Holdings, Inc. was founded in 1964 and is headquartered in Jacksonville, Florida.

ClearPoint Neuro stock logo

ClearPoint Neuro NASDAQ:CLPT

$11.54 -0.54 (-4.47%)
Closing price 04:00 PM Eastern
Extended Trading
$11.82 +0.28 (+2.46%)
As of 04:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Tandem Diabetes Care stock logo

Tandem Diabetes Care NASDAQ:TNDM

$20.76 -0.16 (-0.76%)
Closing price 04:00 PM Eastern
Extended Trading
$20.77 +0.01 (+0.05%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.